Back to today’s briefing

Story perspectives

Novartis' Ianalumab: Game-Changer for Sjögren's Disease Treatment

8/11/2025

39 9

Summary

Story summary

Novartis' Ianalumab (VAY736) is on the brink of revolutionizing Sjögren's disease treatment as the first targeted therapy. Phase III trials revealed remarkable improvements in disease activity and a strong safety profile. With FDA Fast Track Designation, global approval is anticipated by March 2026, offering hope to millions suffering from this condition.

1 of 1

Story summary

Novartis' Ianalumab (VAY736) is on the brink of revolutionizing Sjögren's disease treatment as the first targeted therapy. Phase III trials revealed remarkable improvements in disease activity and a strong safety profile. With FDA Fast Track Designation, global approval is anticipated by March 2026, offering hope to millions suffering from this condition.